These are the most-read DIGITIMES Asia stories from January 20 – January 31.

BEIJING, Feb 6 (Reuters) - Chinese electric vehicle maker BYD (002594.SZ), opens new tab plans to hire 20,000 employees in Zhengzhou in the first quarter, in areas including R&D and manufacturing ...

With overseas sales surging 83% last month, BYD is looking for even more market share in 2025. BYD sets new overseas EV sales record in January 2025 BYD sold over 300,500 new energy vehicles (NEVs ...

Jabil's diversification in end markets, particularly Auto & Transportation and Healthcare & Packaging, is driving revenue ...

There are 3 BYD Electric cars currently available for sale at starting price Rs 24.99 Lakh Lakh. The most popular BYD Electric cars are BYD Seal (Rs. 41 - 53 Lakh), BYD Atto 3 (Rs. 24.99 - 33.99 ...

The Atto 2 ‘Boost’ will offer up to 194 miles of range, and despite keen pricing, BYD is promising generous kit levels onboard, including lots of tech inside. The Atto 2 also benefits from ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances ...

This is the Atto 2, BYD’s all-new B-segment electric SUV. It follows the much larger Sealion 7 and is pointed at one of the largest growing – and competitive – sectors in the electric car ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best ...